Ketul Shah, MD
Urology · Westerville, OHNPI 1265630230
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (51.3%), food and beverage and education — rather than concentrated in one kind of arrangement. Medtronic accounts for 64.0% of it on its own, with 9 other manufacturers making up the rest.
Across 51 payments — averaging $82.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Boston Scientific$932
- Astellas Pharma US Inc$280
- Sumitomo Pharma America, Inc.$178
- Therapeuticsmd, Inc.$40
- AbbVie$27
- plus $60 from 4 others
Across 15 payments — averaging $2238.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$34K
What the payments were for
- Travel & lodging$2,16351%
- Food & beverage$1,90045%
- Education$1554%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 26 | $2,701 |
| Boston Scientific | 11 | $932 |
| Astellas Pharma US Inc | 3 | $280 |
| Sumitomo Pharma America, Inc. | 2 | $178 |
| Therapeuticsmd, Inc. | 3 | $40 |
| AbbVie(2 entities) | 2 | $27 |
| Bluewind Medical | 1 | $24 |
| Endo Pharmaceuticals Inc. | 1 | $17 |
| Coloplast | 1 | $14 |
| Ambu Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,217 in reported general payments places this provider in the 60th percentile of 485 urology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 561 | $460,253 |
| GemtesaVibegron | 62 | $55,133 |
| Methenamine Hippurate | 359 | $40,307 |
| Solifenacin Succinate | 525 | $27,743 |
| Mirabegron ErMirabegron | 34 | $27,620 |
| Estradiol | 128 | $8,800 |
| Trospium Chloride | 125 | $8,222 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 103 | $6,347 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 301 | $5,626 |
| Bethanechol Chloride | 50 | $4,591 |
| Tamsulosin Hcl | 378 | $3,556 |
| Oxybutynin Chloride ErOxybutynin Chloride | 134 | $3,322 |
| Desmopressin Acetate | 30 | $2,394 |
| Trospium Chloride ErTrospium Chloride | 14 | $2,054 |
| Finasteride | 187 | $2,011 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $280 | $460,253561 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $178 | $55,13362 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 485 urology providers in Ohio.
Other urology in Westerville
- Lawrence GervasiMiddleburg Heights$1.1M
- Howard GoldmanCleveland$721K
- Ronney AbazaWorthington$374K
- Sriharan SivalingamCleveland$276K
- Sandip VasavadaCleveland$263K
- Jihad KaoukCleveland$234K
- Benjamin MartinGahanna$205K
- Ruben OlivaresCleveland$184K
- Abhinav SidanaCincinnati$174K
- Raymond RackleyCleveland$152K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.